Ms. Yeh-Huang, Chun-Ying (黃純瑩), General Manager
Born in 1959, Ms. Yeh-Huang joined the Group on July 5, 2010. She currently serves as an executive Director and the general manager of the Company. She is also a member of the Strategy Committee. Ms. Yeh-Huang oversees the Group’s overall strategic direction and various aspects of the Company’s operations and management, including human resources, business development, internal coordination and external communications with regulators and business partners.
From April 1986 to December 2015, Ms. Yeh-Huang worked at TTY Biopharm Company Limited and during which she became an executive vice president of the oncology science business development unit in April 2011. She was a pharmacist of Veteran General Hospital from July 1983 to August 1985.
Ms. Yeh-Huang obtained a bachelor’s degree in pharmacy from Taipei Medical University in Taiwan in June 1982. She obtained her Taiwan license of pharmacist from June 1983.
Dr. Liu, Jun (劉軍), Vice General Manager
Born in 1967, Dr. Liu joined the Group on October 17, 2016 as a vice general manager and was appointed as an executive Director on October 26, 2018 and chief scientific officer on March 12, 2019. He is responsible for quality control of biological drug candidates, biopharmaceutical project analysis methods and drugs quality assurance.
Prior to joining the Group, Dr. Liu was the executive director of biologics research and development department in Shanghai ChemPartner Co. Ltd, Shanghai, the PRC between July 2010 and October 2016.
Dr. Liu obtained a Ph.D. in bioanalytical chemistry from the University of California, Davis, in the United States in December 2002 and a bachelor’s degree in chemistry from the University of Science & Technology of China in Hefei, Anhui Province, the PRC in July 1991.
Mr. Fu, Shan (付山), Chairman
Born in 1968, Mr. Fu joined the Group on January 19, 2016 as a non-executive Director and was appointed the chairman of the Board on September 28, 2018. He is also the chairman of the Nomination Committee and the Strategy Committee. He has previously used the Chinese name “Fu Shan (傅山)”
Mr. Fu obtained a master's degree in history and a bachelor's degree in history, both from Peking University in Beijing, the PRC, in 1991 and 1988, respectively.
Mr. Kung, Frank Fang-Chien
Born in 1948, Mr. Kung joined the Group on January 19, 2016 as a non-executive Director. Mr. Kung was a founder and has since 1997 been a managing partner of Vivo Capital LLC, which is an investment management firm that primarily invests in the field of biotechnology and healthcare. He was the founder and has since 1983 been the president and CEO of Genelabs Technologies Inc., a biopharmaceutical company engaged in the discovery and development of infections disease therapies. He has also been a director of Sagent Pharmaceuticals since 2010. He has been a director of Amyris, Inc. (NASDAQ: AMRS) since November 2017.
Mr. Kung obtained a Ph.D. in molecular biology from the University of California, Berkeley in the United States, in 1976, and a bachelor's degree in chemistry from National Tsinghua University in Hsinchu City, Taiwan in 1970.
Mr. Kang, Pei
Born in 1958, Mr.Kang joined the Group on January 11, 2011 as non-executive Director. He is also a member of the Remuneration Committee. He has been the executive director of Chengwei Investment Management Advisory (Shanghai) Co., Ltd. (an entity under venture capital firm Chengwei Ventures LLC) since March 2003. Mr. Kang worked in various IBM Asian Pacific entities from January 1983 to May 2000, and his last position held was the executive in the financial service sector. He has been a director of Transn IOL Technology Co., Ltd., (National Equities Exchange and Quotations of the PRC: 835737) since August 2015. Mr. Kang was a non-executive director of AAC Technologies Holding Ltd. (Hong Kong Stock Exchange: 2018) from February 2007 to May 2010.
Mr. Kang obtained a bachelor's degree in labor relations from Chinese Culture University in Taipei, Taiwan in June 1980.
Mr. Qiu, Yu Min
Born in 1973, Mr. Qiu joined the Group on September 26, 2018 as a non-executive Director. He is also a member of the Audit and Connected Transactions Review Committee. He has been a partner of private equity fund Advantech Capital since October 2017. From January 2016 to September 2017, he was an executive director at Advantech Capital. He served at private equity fund New Horizon Capital as an executive director from January 2015 to December 2015 and as a director from May 2013 to December 2014.
Mr. Qiu obtained a Master of Business Administration from the University of British Columbia in Vancouver, Canada in May 2004 and a bachelor's degree in engineering from East China University of Technology in Shanghai, the PRC in July 1994. He was certified as a Chartered Financial Analyst in October, 2007 by the CFA Institute and a Certified Management Accountant in 2006 by the Institute of Management Accountants.
Independent non-executive director：
Ms. Hu, Lan
Born in 1971, Ms. Hu joined the Group on March 12, 2019 as an independent non-executive Director. She is the chairlady of the Audit and Connected Transactions Review Committee.
Ms. Hu has more than 20 years of experience in accounting. Ms. Hu was the partner of the consulting services department of PricewaterhouseCoopers between July 2008 and June 2018. Prior to that, she worked at PricewaterhouseCoopers from July 2002. She worked at Arthur Andersen from July 1994 to June 2002.
Ms. Hu obtained an MBA degree from University at Buffalo, the State University of New York, in U.S in February 2005 and a bachelor’s degree in accounting from Beijing Machinery and Industrial Institute in Beijing, the PRC in July 1994. She gained her Chinese Institute of Certified Public Accountants qualification in March 1997.
Mr. Sun, Lijun Richard
Born in 1962, Mr. Sun joined the Group on March 12, 2019 as an independent non-executive Director. He is also a member of the Remuneration Committee, the Nomination Committee and the Strategy Committee.
Mr. Sun has more than 20 years of experience in drug discovery and development, having been named as an inventor of more than 100 awarded US patents that include drug discoveries related to cancer, autoimmune diseases and inflammatory dieases since 1999. He has also authored 35 peer-reviewed publications on biotechnology. He has worked at the Department of Surgery of the Beth Israel Deaconess Medical Center as the Director of the Center for Drug Discovery and Translational Research, with an academic appointment at Harvard Medical School as Associate Professor from 2012.
Mr. Sun received his master of science degree from Georgetown University in Washington, D.C., the United States in 1992, and PhD degree in May 1996 in Georgia, the United States from Emory University. He was also a research fellow at the Emory University School of Medicine in 1997.
Mr. Chang, Hong-Jen
Born in 1956, Mr. Chang joined the Group on March 12, 2019 as an independent non-executive Director. He is also a member of the Audit and Connected Transactions Review Committee and the Strategy Committee. He is also the chairman of the Remuneration Committee. He has over 14 years of experience in biotech investment.
Mr. Chang has served as the President of Taiwan Research-based Biopharmaceutical Manufacturers Association from May 2017, an adjunct professor of Institute of Public Health, National Yang-Ming University from August 2018, the Chairman of YFY Biotech Management Co., Ltd. from July 2005, the Chairman of MiCareo Taiwan Co., Ltd. from July 2011, and the Chairman of EUSOL Biotech Co., Ltd. (Taipei Exchange: 6652) from October 2009.
Mr. Chang obtained his bachelor of medicine degree from National Yang-Ming Medical College in June 1982, master of public health degree from National Taiwan University in Taiwan in June 1984 and master of science in health services administration degree from Harvard University in the United States in June 1987.